Form 8-K LIGAND PHARMACEUTICALS For: Aug 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Roth Still Positive on Ligand (LGND) Following Q2 Results, ASPIRE Phase 3 Update (AMGN)
August 4, 2014 2:24 PM EDTRoth Capital affirms Ligand Pharma (Nasdaq: LGND) with a Buy rating and $92 price target following Q2 results and update issued earlier Monday.
Analyst Joseph Pantginis commented We believe LGND is in its strongest financial position to date with a growing cash balance, debt fully... More
Ligand Pharmaceuticals, Inc. (LGND) Tops Q2 EPS by 10c; Boosts FY14 Outlook
August 4, 2014 8:40 AM EDTLigand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q2 EPS of $0.24, $0.10 better than the analyst estimate of $0.14. Revenue for the quarter came in at $10.6 million versus the consensus estimate of $9.73 million.
Ligand Pharmaceuticals, Inc. sees Q3 2014 EPS of $0.26-$0.29, versus the consensus of $0.4. Ligand... More
